ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Pharmaceuticals

Takeda to sell OTC drug unit to Blackstone for $2.3bn

Japanese pharmaceutical maker in bid to reduce debt inflated by Shire purchase

Takeda Pharmaceutical will sell wholly owned subsidiary Takeda Consumer Healthcare Company, which is involved in Alinamin and other medicine line.

TOKYO -- Japan's Takeda Pharmaceutical has decided to sell its nonprescription drugs business, including vitamin drug Alinamin, to major U.S. private equity firm Blackstone Group for about 250 billion yen ($2.37 billion)

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more